Copyright
©2008 The WJG Press and Baishideng.
World J Gastroenterol. Sep 7, 2008; 14(33): 5162-5175
Published online Sep 7, 2008. doi: 10.3748/wjg.14.5162
Published online Sep 7, 2008. doi: 10.3748/wjg.14.5162
Combined treatment of doxorubicin and Rosco | Combination interaction at various durations of treatment in human colorectal cancer cells1 | ||||||||
SW48 | SW1116 | SW837 | |||||||
2 d | 4 d | 6 d | 2 d | 4 d | 6 d | 2 d | 4 d | 6 d | |
Dox 0.5 IC50 + Rosco 1.0 μg/mL | ant | ant | ant | syn | syn | syn | syn | syn | syn |
Dox 1.0 IC50 + Rosco 10 μg/mL | ant | ant | ant | syn | syn | syn | syn | syn | syn |
Dox 2.0 IC50 + Rosco 15 μg/mL | ant | ant | ant | syn | syn | syn | syn | syn | syn |
Dox 3.0 IC50 + Rosco 20 μg/mL | ant | add | add | syn | syn | add | syn | syn | add |
Dox 4.0 IC50 + Rosco 25 μg/mL | ant | add | add | syn | ant | add | syn | ant | ant |
- Citation: Abaza MSI, Bahman AMA, Al-Attiyah RJ. Roscovitine synergizes with conventional chemo-therapeutic drugs to induce efficient apoptosis of human colorectal cancer cells. World J Gastroenterol 2008; 14(33): 5162-5175
- URL: https://www.wjgnet.com/1007-9327/full/v14/i33/5162.htm
- DOI: https://dx.doi.org/10.3748/wjg.14.5162